SCHEMBL4991496

SCHEMBL4991496

O=C1Nc2ccccc2/C1=C\Nc1ccc(CCCCN2CCOCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.45
POLB P06746 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
FGFR1 P11362 1/20 0.42
KDR P35968 1/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
HTR6 P50406 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HTT P42858 2/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PAK1 Q13153 6/20 0.41
FLT3 P36888 2/20 0.41
KMT2A Q03164 1/20 0.40
PARP1 P09874 2/20 0.40
LRRK2 Q5S007 1/20 0.40
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4991508 1.00 PDGFRB (0.45) PDGFRBPOLBSIGMAR1FGFR1KDR
SCHEMBL4993948 0.93 PDGFRB (0.47) PDGFRBFGFR1KDRPAK1FLT3
SCHEMBL4993943 0.93 PDGFRB (0.47) PDGFRBFGFR1KDRPAK1FLT3
SCHEMBL4999210 0.90 SIGMAR1 (0.46) PDGFRBSIGMAR1FGFR1KDRALDH1A1
SCHEMBL4999214 0.90 SIGMAR1 (0.46) PDGFRBSIGMAR1FGFR1KDRALDH1A1
SCHEMBL4990918 0.88 LRRK2 (0.54) PDGFRBFGFR1KDRPAK1FLT3
SCHEMBL4990924 0.88 LRRK2 (0.54) PDGFRBFGFR1KDRPAK1FLT3
SCHEMBL4993361 0.87 NPC1 (0.46) PDGFRBFGFR1KDRALDH1A1CRHBP
SCHEMBL4993353 0.87 NPC1 (0.46) PDGFRBFGFR1KDRALDH1A1CRHBP
SCHEMBL4995812 0.87 FLT3 (0.43) PDGFRBFGFR1KDRPAK1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885POLB 2450/4885SIGMAR1 2218/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885POLB 2450/4885SIGMAR1 2218/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885POLB 2450/4885SIGMAR1 2218/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885POLB 2450/4885SIGMAR1 2218/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885POLB 2450/4885SIGMAR1 2218/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885POLB 2450/4885SIGMAR1 2218/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 PDGFRB 307/4885POLB 2450/4885SIGMAR1 2218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.